FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2416 May 29, 2008 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

Edited by Dieter Marmé and Norbert Fusenig. 845 pp., illustrated. Berlin, Springer, 2008. $369. ISBN 978-3-540-33176-6.

In January, the world lost a visionary in cancer research, M. Judah Folkman. Folkman, who died while traveling to a Keystone symposium to give the keynote address, proposed nearly four decades ago that attacking the tumor vasculature could improve outcomes for patients with cancer in its advanced stages. These insights provided the foundation for the development of antiangiogenic therapies and changed the standard of care for patients with specific cancers (as well as for patients with ocular macular degeneration). It is fitting that this book, Tumor Angiogenesis, begins with a chapter written by Folkman in which he comprehensively reviews the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.